BECN1 and breast carcinoma: Therefore, the present study aimed to evaluate the modulatory effect of regorafenib on the P2X7/HIF-1α/VEGF, P2X7/P38, P2X7/ERK/NF-κB, and P2X7/beclin 1 pathways on the MCF7 breast cancer cell line and its impact on different signaling pathways involved in breast cancer progression.